الصفحة 16
الصفحة 16
Chemistry and pharmacology of drug discovery
Illustrates how chemistry, biology, pharmacokinetics, and a host of disciplines come together to produce successful medicines, discussing a total of 20 drugs that are all FDA-approved post 2021. Cover Infectious Disease, Cancer Drugs, CNS Drugs, and Miscellaneous Drugs. Each chapter covers background material on the drug class and/or disease indication and key aspects relevant to the discovery of the drug, including structure-activity relationships, pharmacokinetics, drug metabolism, efficacy, and safety.
Chemical components in some winter vegetables and their effectiveness in treating diseases
Cruciferous (Brassicaceae) vegetables comprise many important species cultivated worldwide and utilized traditionally for culinary and medicinal purposes in different cultures. In the last couple of decades, growing scientific evidence has suggested that consumption of cruciferous vegetables has a preventive role against a variety of human diseases. This prompted the development of nutritional ingredients derived from these vegetables and their use as dietary supplements in different formulations that contain complete plant extracts or specific compounds...
Checkpoint Responses in Cancer Therapy
This book’s distinguished panel of authors takes a close look at topics ranging from the major molecular players affecting DNA synthesis and the response to DNA damage to advances made in the identification of chemical compounds capable of inhibiting individual mitotic kinases. Illuminating and authoritative, Checkpoint Responses in Cancer Therapy offers a critical summary of findings for researchers in the pharmaceutical and biotechnology industries and a valuable resource for academic scientists in cancer research and the study of cell-cycle regulation, signal transduction and apoptosis.
Cell therapy stem cells and regenerative medicine
Provides an overview of cell-based therapy for human diseases including the definition, history, and clinical applications of human stem cells and their use in regenerative medicine. It covers human pluripotent stem cells (human embryonic stem cells and human induced pluripotent stem cells), mesenchymal stem/stromal cells, and hematopoietic stem cells, bone marrow mononuclear cells. In terms of clinical applications, this book also provides an update on recent human trials using these cells to treat various diseases, including neurological disorders, pulmonary dysfunctions, metabolic/endocrine-related diseases, frailty, and cancer treatment. In addition, it discusses the authors’ clinical trial experiences related to these conditions in a clinical setting to provide additional insight into regenerative medicine, especially cell-based therapy.
Cell Motility in Cancer Invasion and Metastasis
Cancer Morbidity and mortality result from invasive and metastatic spread. Currently, no therapies are aimed at the underlying mechanisms that enable this progression due to only nascent recognition of the distinct biology which occurs only during tumor dissemination. Recent advances have highlighted the central role of cell motility during the dynamic and transient process of tumor invasion and metastasis. This book includes state-of-the-art updates by international leaders in these studies. Chapters first present the novel model systems that enable new investigations and insights. Chapters then describe in depth the key processes and molecules that may be therapeutically targeted. Finally, the role of cell motility and its signals is explored in a number of key tumor types. This compilation should be useful to researchers in basic and translational oncology as well as those developing novel agents to prevent tumor invasion and metastasis.
Cell Cycle Regulation
The cell cycle is tightly regulated on many different levels to ensure properly controlled proliferation. Deregulation of cell cycle regulation is a hallmark of cancer. In this book, many aspects of cell cycle regulation are discussed, which include G1, S, M phase control, ubiquitin-mediated degradation, DNA damage response, mitotic spindle checkpoint, the centrosome cycle, Retinoblastoma protein family, the Myc oncogene, and mouse models for tumor suppressors, cyclin-dependent kinases, and meiosis. These chapters written by experts provide an updated view on how the cell cycle is regulated in vivo and about the involvement of cell cycle regulators in cancer.
Cell Adhesion and Cytoskeletal Molecules in Metastasis
In this volume, the expression of specific adhesion molecules within human cancer tissues are highlighted. The expression signatures from published DNA microarray and immunohistochemistry studies are detailed. The concept that the alteration of specific adhesion molecules influence the cancer migration ability and cancer damage responses is detailed in this volume; both features are essential for the survival of an invading tumor cell. Defining the minimal adhesion receptors preserved on cancer cells during tumor progression will define the metastatic adhesion signature. Understanding the metastatic adhesion signature will reveal vulnerabilities that could be exploited for the prevention and/or eradication of the invading cancer cell.
CD4+CD25+ Regulatory T Cells : Origin, Function and Therapeutic Potential
CD4+CD25+ regulatory T cells (Treg) and interleukin-10 producing T regulatory 1 (Tr1) cells have been studied in most detail and are the subject of most articles in this issue. Treg, also called "natural" regulatory T cells, will be traced from their intra-thymic origin to the site of their action in peripheral lymphoid organs and tissues.
CD137 Pathway : Immunology and Diseases
This comprehensive volume, written by experts in the field, covers nearly all aspects of ongoing research related to the CD137 pathway. Recent research has shown that the manipulation of CD137 pathway molecules is very promising in the treatment of cancer, viral infection, transplantation rejection and autoimmune diseases in experimental animal models. The volume includes research related to the identification and understanding of functional consequences of CD137 receptor and ligand molecules which represents a major effort in the field of immunology. CD137 Pathway: Immunology and Diseases is an ideal book for immunologists, microbiologists, cancer researchers, molecular biologists, biochemists, and pharmaceutical and biotechnology company scientists.
Care of head and neck cancer patients for dental hygienists and dental therapists
An advisory guide that enables dental hygienists, dental therapists, and other health care professionals to appreciate the journey undertaken by head and neck cancer patients. Focusing on the before, during, and after treatments, the book covers common head and neck cancer treatments such as surgery, radiotherapy, chemotherapy and innovative new therapies. It also discusses treatment complications such as halitosis, osteoradionecrosis, and radiation dermatitis.
Carcinoma della cervice uterina : Eziopatogenesi e profilassi = Carcinoma of the uterine cervix : Aetiopathogenesis and prophylaxis
The volume offers a synthetic and updated picture of a complex topic that includes the multifactorial etiopathogenesis of cervical cancer, the characteristics of the virus, the dynamics of HPV infections, the histological lesions of the cervix leading to cervical cancer. and the characteristics of the various surgical treatments, the current strategies for early diagnosis through the use of molecular assays currently on the market, up to the trials of the two vaccines recently registered also in Italy.
Cannabinoids as Therapeutics
this volume concentrates on the diseases, the physiological effects and therapeutic use of cannabinoids. The volume editor Prof. Mechoulam was the first who isolated the prime active constituent (THC, Tetrahydrocannabiol) of marijuana. He published extensively on the pharmacological activities of cannabinoids. The volume is of interest to researchers and clinicians from pharmacology, neuroscience, and medicinal research
Cancerimmunotherapies : Solid tumors and hematologic malignancies
Presents the clinical scope of cancer immunotherapeutic agents for solid tumors and Hematologic malignancies, elaborates on the scientific details of their modes of action, and presents the impact of these agents on oncology, patients and the broader healthcare system. At present, cancer immunotherapies fall broadly into three categories: immune checkpoint inhibitors (ICIs), adoptive T cell therapies, and cancer vaccines which have distinct mechanisms of action. Immune checkpoint inhibitors rely upon disrupting tumor antigen recognition as self by the immune system through inhibition of checkpoint molecules. Adoptive T cell therapies involve the engineering of T cells ex vivo to target and destroy tumor cells. The first part of this book will provide an overview of the discovery and mechanistic details of the technology. The second part will be devoted to elaborating on the clinical outcomes, successes and limitations for specific tumor subtypes, which includes both solid tumors and hematologic malignances for both pediatric and adult populations.
Cancer vaccination and challenges Vol.2 : delivery strategies for cancer vaccine and immunotherapy in the management of various carcinomas
Covers delivery strategies of cancer vaccines for the management of various forms of carcinoma, examining the prospects of delivering immuno-oncology therapies, focusing specifically on effective drug delivery strategies for the treatment of lung, prostate, and pancreatic carcinomas.
Cancer vaccination and challenges Vol.1 : strategies for therapeutic cancer vaccine development
Deals with different strategies of cancer vaccine development, focusing on techniques for the development of therapeutic cancer vaccines and the roles of tumor antigens, proteins/peptides, microbial genes, and stem cells for the development of vaccines for cancer management.
Cancer Survivorship : Today and Tomorrow
A diagnosis of cancer provokes myriad responses in patients, chief among them the question: "how long do I have to live?" Increasingly, the answer to that question is not one of months or years, but decades. While there are now nearly 10 million people in the United States who have recovered or are currently recovering from cancer (increased from three million in 1971), the unique challenges encountered by survivors are often met with uncertainity by even the most seasoned physicians, nurses, and clinical social workers because of a lack of formal guidelines for post-treatment care and follow-up.
Cancer Stem Cells : Novel Concepts and Prospects for Tumor Therapy
This book describes the recent developments in the emerging field of cancer stem cells. Their possible impact for the identification of novel treatment paradigms for cancer are discussed. The book will mainly be of interest to scientists and clinicians involved in cancer research, or to students wishing to enter into this area.
Cancer Research Center = مركز أبحاث للسرطان
المشروع يضم عباره عن قسم أبحاث للسرطان و قسم معاينه وعلاج للمرضى المتطوعين للتجارب السريره ملحقه باقامه مؤقته و دائمه ويضم مدرج لالقاء المحاضرات النظريه والعمليه من قبل المختصيين والباحثيين وأخيرا يضم سكن لأطباء والباحثيين
Cancer Proteomics : From Bench to Bedside
the authors collectively provide the current status of proteomics in cancer therapy and offers the existing technologies used in proteomics that allow for protein profiling and for the identification of druggable targets in human samples. Mass spectrometry based protein characterization and protein microarrays hold great promise of predicting response to specific drugs in cancer therapy. Insightful to the reader with broad perspectives on topics related to the use of proteomic strategies in cancer therapy, Cancer Proteomics offers anticipated challenges that may arise from its application in daily practice.
Cancer Prevention
This volume contains the main proceedings of the fourth international conference on "Cancer Prevention 2006," which was held during February 16–18, 2006, in St. Gallen, Switzerland. Written by international experts in the field, the book comprises a comprehensive update on the most recent developments in the upsurging fields of molecular biology and cancer genetics and their interactions with clinical epidemiology and cancer prevention at various levels: genetic/biologic predisposition and definition of high-risk groups; preclinical models and tumor prevention; prospects of surrogate endpoints and biomarkers; progress in imaging and detection of neoplastic precursor lesions.
